Yellow Micropulse Laser in Diabetic Macular Edema: A Short-Term Pilot Study

Abstract

Purpose

To evaluate the effects of yellow micropulse laser in eyes with diabetic macular edema (DME).

Methods

In this retrospective interventional case series, 22 eyes of 17 patients with visual impairment secondary to persistent DME received one single session of yellow micropulse laser. Patients were divided into 2 groups: group 1, naive eyes; and group 2, previously treated eyes. Main outcome measures included changes in central retinal thickness (CRT) and best-corrected visual acuity (BCVA). Possible atrophic changes of the retinal pigment epithelium as a result of yellow micropulse laser application were evaluated with fundus autofluorescence.

Results

At baseline, the mean logMAR BCVA was 0.39 ± 0.18 and the mean CRT was 361.8 ± 70.95. The mean BCVA improved to 0.31 ± 0.19 (p = 0.0091) and 0.31 ± 0.19 (p = 0.0078) at 3 and 6 months of follow-up, respectively. The mean CRT improved to 331.3 ± 48.46 (p<0.0001) and 328.1 ± 53.25 (p<0.0001) at 3 and 6 months of follow-up. Subgroup analysis showed that only in naive eyes was there a beneficial effect on visual acuity and central macular thickness.

Conclusions

In eyes with DME, yellow micropulse laser produces a statistically significant improvement in BCVA and CRT in the short term.

Keywords

Diabetic retinopathy Macular edema Micropulse Yellow micropulse laser

Get full access to this article

View all access options for this article.

References

Klein

Moss

S.E.

Klein

B.E.

Davis

M.D.

DeMets

D.L.

The Wisconsin epidemiologic study of diabetic retinopathy. XI. The incidence of macular edema. Ophthalmology 1989; 96: 1501–10.

Lang

G.E.

Berta

Eldem

B.M.

; RESTORE Extension Study Group. Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: interim analysis of the RESTORE extension study. Ophthalmology 2013; 120: 2004–12.

Elman

M.J.

Qin

Aiello

L.P.

; Diabetic Retinopathy Clinical Research Network. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology 2012; 119: 2312–8.

Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol 1985; 103: 1796–806.

Shah

A.M.

Bressler

N.M.

Jampol

L.M.

Does laser still have a role in the management of retinal vascular and neovascular diseases?

Am J Ophthalmol 2011; 152: 332–9.

Mainster

M-A

. Decreasing retinal photocoagulation damage: principles and techniques. Semin Ophthalmol 1999; 14: 200–9.

Blumenkranz

M.S.

Optimal current and future treatments for diabetic macular oedema. Eye 2010; 24: 428–34.

Lange

C-A

Stavrakas

Luhmann

U.F.

Intraocular oxygen distribution in advanced proliferative diabetic retinopathy. Am J Ophthalmol 2011; 152: 406–12.

Hudson

Flanagan

J.G.

Turner

G.S.

Chen

H.C.

Young

L.B.

McLeod

Influence of laser photocoagulation for clinically significant diabetic macular oedema (DMO) on short-wavelength and conventional automated perimetry. Diabetologia 1998; 41: 1283–92.

10.

Schatz

Madeira

McDonald

H.R.

Johnson

R.N.

Progressive enlargement of laser scars following grid laser photocoagulation for diffuse diabetic macular edema. Arch Ophthalmol 1991; 109: 1549–51.

11.

Lewis

Schachat

A.P.

Haimann

M.H.

Choroidal neovascularization after laser photocoagulation for diabetic macular edema. Ophthalmology 1990; 97: 503–10; discussion 510–1.

12.

Guyer

D.R.

D'Amico

D.J.

Smith

C.W.

Subretinal fibrosis after laser photocoagulation for diabetic macular edema. Am J Ophthalmol 1992; 113: 652–6.

13.

Striph

G.G.

Hart

W.M.

Jr. Olk

R.J.

Modified grid laser photocoagulation for diabetic macular edema. The effect on the central visual field. Ophthalmology 1988; 95: 1673–9.

14.

Bandello

Polito

Del Borrello

Zemella

Isola

“Light” versus “classic” laser treatment for clinically significant diabetic macular oedema. Br J Ophthalmol 2005; 89: 864–70.

15.

Fong

D.S.

Strauber

S.F.

Aiello

L.P.

; Writing Committee for the Diabetic Retinopathy Clinical Research Network. Comparison of the modified Early Treatment Diabetic Retinopathy Study and mild macular grid laser photocoagulation strategies for diabetic macular edema. Arch Ophthalmol 2007; 125: 469–80.

16.

Luttrull

J.K.

Musch

D.C.

Mainster

M.A.

Subthreshold diode micropulse photocoagulation for the treatment of clinically significant diabetic macular oedema. Br J Ophthalmol 2005; 89: 74–80.

17.

Laursen

M.L.

Moeller

Sander

Sjoelie

A.K.

Subthreshold micropulse diode laser treatment in diabetic macular oedema. Br J Ophthalmol 2004; 88: 1173–9.

18.

Luttrull

J.K.

Musch

D.C.

Mainster

M.A.

Subthreshold diode micropulse photocoagulation for the treatment of clinically significant diabetic macular oedema. Br J Ophthalmol 2005; 89: 74–80.

19.

Figueira

Khan

Nunes

Prospective randomised controlled trial comparing sub-threshold micropulse diode laser photocoagulation and conventional green laser for clinically significant diabetic macular oedema. Br J Ophthalmol 2009; 93: 1341–4.

20.

Vujosevic

Bottega

Casciano

Pilotto

Convento

Midena

Microperimetry and fundus autofluorescence in diabetic macular edema: subthreshold micropulse diode laser versus modified early treatment diabetic retinopathy study laser photocoagulation. Retina 2010; 30: 908–16.

21.

Lavinsky

Cardillo

J.A.

Melo

L.A.

Jr. Dare

Farah

M.E.

Belfort

Jr. . Randomized clinical trial evaluating mETDRS versus normal or high-density micropulse photocoagulation for diabetic macular edema. Invest Ophthalmol Vis Sci 2011; 52: 4314–23.

22.

Vujosevic

Martini

Convento

Subthreshold laser therapy for diabetic macular edema: metabolic and safety issues. Curr Med Chem 2013; 20: 3267–71.

23.

Mainster

M.A.

Wavelength selection in macular photocoagulation. Tissue optics, thermal effects, and laser systems. Ophthalmology 1986; 93: 952–8.